Asset sale Announced Sponsor exit
DRI Healthcare Trust acquisition of Royalty participation rights in U.S. net sales of tavapadon
US$316m consideration
Announced 21 Sep 2026
Advisers
Royalty participation rights in U.S. net sales of tavapadon
Target
Not disclosed
DRI Healthcare Trust
Acquirer
- Legal adviser
- Target
- Royalty participation rights in U.S. net sales of tavapadon
- Acquirer
- DRI Healthcare Trust
- Seller
- Bain Capital
- Target based in
- United States
- Buyer based in
- Canada
- Seller based in
- United States
- Sector
- Specialty finance and leasing
- Tags
- Specialty finance and leasing, Pharma, Asset & Wealth Management
In the league tables
Similar deals
- Royalty Pharma acquisition of PTC Therapeutics' remaining royalty on Roche's Evrysdi Jan 2026 · US$240m · Specialty finance and leasing
- Anchorage Capital Advisors, L.P. acquisition of 11 U.S.-based CLO management contracts managed by ORIX Advisers Sep 2026 · Asset & Wealth Management
- HealthCare Royalty acquisition of Modeyso commercial sales royalties Apr 2026 · Specialty finance and leasing
- Universities Superannuation Scheme acquisition of Venn Partners LLP Mar 2026 · Asset & Wealth Management
- Chicago Atlantic Real Estate Finance merger Jun 2026 · US$303m · Specialty finance and leasing
Sources
- 21 Sep 2026 DRI Healthcare’s Acquisition of Royalty Participation Rights in U.S. Net Sales of tavapadon cravath.com
